Eli Lilly acquired Adverum, gaining access to Ixo-vec, a gene therapy for wet age-related macular degeneration. Read why I ...

Adverum Biotechnologies (($ADVM)) announced an update on their ongoing clinical study. Adverum Biotechnologies is conducting a Phase 3 clinical ...

Eli Lilly plans to acquire a gene therapy developer that once planned a 200-job facility in Research Triangle Park.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK, Oct. 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest ...

Eli Lilly and Company and Adverum Biotechnologies, a clinical-stage gene therapy company aiming to preserve sight for life in ...

Eli Lilly and Company has agreed to acquire Adverum Biotechnologies Inc., a clinical-stage company pioneering the use of intravitreal gene therapy.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum shareholders. Under the ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

Eli Lilly to buy gene therapy developer, Adverum Biotechnologies: Indianapolis Monday, October 27, 2025, 10:00 Hrs [IST] Eli Lilly and Company and Adverum Biotechnologies, Inc., a ...

Indianapolis: Eli Lilly and Company and Adverum Biotechnologies, Inc., a clinical-stage company, have announced a definitive ...

US pharma major Eli Lilly shares closed up 2.8%, while those of Adverum Biotechnologies dropped 2.4% to $4.28, on news of a ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM) ...